Waters Corporation (NYSE:WAT) Receives Average Rating of "Moderate Buy" from Analysts
Waters Corporation (NYSE:WAT) has received a consensus "Moderate Buy" rating from twenty analysts, with an average 12-month price target of $390.44. The company recently exceeded quarterly earnings estimates and issued strong FY2026 guidance. Insider trading shows Director Wei Jiang increased his stake by purchasing 500 shares, bringing insider ownership to 0.63% and institutional ownership to 94.01%.
Agilent CLO Departing With Severance After Less Than 2 Years in Role
Agilent's Chief Legal Officer, Bret DiMarco, is leaving the company with severance after less than two years in the role. DiMarco, a Silicon Valley veteran, will remain as a special adviser until December 1st. The article notes that a subscription is required to access the full content.
Evercore Maintains Agilent Technologies(A.US) With Buy Rating, Cuts Target Price to $140
Evercore has reiterated its Buy rating on Agilent Technologies (A.US), a prominent analytical instrumentation and laboratory services company. However, the firm has adjusted its target price downwards to $140. This revision reflects a nuanced outlook, maintaining confidence in the company's long-term prospects while acknowledging potential near-term adjustments.
Evercore ISI Adjusts Agilent Technologies Price Target to $140 From $160, Maintains Outperform Rating
Evercore ISI has revised its price target for Agilent Technologies (NYSE: A) to $140, down from the previous $160, while reiterating an Outperform rating for the stock. This adjustment comes amidst recent news regarding Agilent's activities, including FDA approvals for diagnostic tools and significant acquisition deals. Agilent Technologies specializes in measurement instruments for various sectors, primarily life sciences, electronics, and chemistry.
U.S., Europe And Asia Industrial Hydrogen Market Is Booming
A new report by Coherent Market Insights forecasts significant growth for the U.S., Europe, and Asia Industrial Hydrogen Market from 2026 to 2033 due to increasing demand, expanding applications, and technological advancements. The study provides insights into market size, revenue trends, key growth factors, and competitive landscape, offering actionable data for businesses. It also highlights major players such as Air Liquide and Linde Plc.
Thermo Fisher Microscopes: Precision in Scientific Imaging
This article details how Thermo Fisher microscopes are crucial for scientific imaging across various research and industrial applications. It highlights their advanced optical and electron models, cutting-edge features like high-resolution optics, fluorescence capabilities, and automation. The article also discusses their market relevance, competitive landscape, ongoing innovations, and significant impact on global health and scientific discovery.
Stocks to Avoid Under $10: iHeartMedia, Energy Recovery, Neogen Analysis | 2026 - News and Statistics
StockStory identifies three specific stocks priced under $10 to avoid in 2026: iHeartMedia (IHRT), Energy Recovery (ERII), and Neogen (NEOG). The firm cautions investors about the speculative nature of low-priced stocks and points out factors like below-sector revenue growth, diminishing returns on capital, and dilution risks for these companies. The article provides a brief analysis of each company's financial health and market position.
Quintet Private Bank Europe S.A. Has $1.26 Million Position in Agilent Technologies, Inc. $A
Quintet Private Bank Europe S.A. significantly reduced its stake in Agilent Technologies (NYSE:A) by 92.3% in Q4, selling over 110,000 shares and retaining a position valued at approximately $1.26 million. Despite Agilent slightly missing Q4 earnings estimates, its revenue increased 7% year-over-year, and the company issued optimistic FY2026 guidance, with analysts maintaining a "Moderate Buy" rating and a consensus target price of $161.20. Other institutional investors showed mixed activity in the stock, while analyst ratings generally leaned towards "Buy" or "Strong Buy."
Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Brokerages
Agilent Technologies, Inc. (NYSE:A) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $161.20. The company recently reported Q4 results that slightly missed estimates but showed a 7% year-over-year revenue increase, and declared a quarterly dividend of $0.255. Several institutional investors have adjusted their holdings in Agilent Technologies, which trades near $115.44 with a market capitalization of approximately $32.6 billion.
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.70 Million Position in Agilent Technologies, Inc. $A
Empirical Financial Services LLC d.b.a. Empirical Wealth Management significantly increased its stake in Agilent Technologies (NYSE:A) by 288.9% in the fourth quarter of 2025, bringing its total holdings to 12,463 shares valued at approximately $1.70 million. This comes as Agilent reported Q4 EPS of $1.36 and revenue of $1.80 billion, with analysts maintaining a "Moderate Buy" rating and an average price target of $161.20, significantly above its current trading price of $115.44. The company also announced a quarterly dividend of $0.255 per share.
Agilent Announces Transition Plan for Chief Legal Officer
Agilent Technologies announced a transition plan for its Chief Legal Officer, Bret DiMarco, who will step down from his current roles by September 30, 2026, or earlier if a successor is appointed. DiMarco will then serve as a Special Advisor until December 1, 2026, with a reduced salary but continued benefits and equity vesting, followed by a lump-sum exit payment. This structured approach aims to ensure a smooth leadership transition and manage executive compensation.
Agilent Technologies announces transition of chief legal officer Bret DiMarco
Agilent Technologies (NYSE: A) announced a leadership transition for its Chief Legal Officer, Bret DiMarco, who will resign from his current roles by September 30, 2026, or when a new CLO starts. Mr. DiMarco will serve as a Special Advisor until December 1, 2026, receiving an annualized salary of $350,000 and continuing to vest in equity awards. The company, valued at $32.6 billion, maintains financial stability with a P/E ratio of 25.34 and a 0.88% dividend yield, having consistently paid dividends for 15 years.
Agilent (NYSE: A) details Chief Legal Officer transition and advisory role
Agilent Technologies, Inc. announced a leadership transition for its Chief Legal Officer role. Bret DiMarco will resign from his current positions by September 30, 2026, or sooner upon the appointment of a new CLO, and will then serve as a Special Advisor until December 1, 2026. During his advisory period, he will receive an annualized base salary of $350,000 and continue vesting in existing equity awards, while forfeiting new equity grants and the 2026 annual bonus.
Louisbourg Investments Inc. Sells 12,946 Shares of Agilent Technologies, Inc. $A
Louisbourg Investments Inc. reduced its stake in Agilent Technologies (NYSE:A) by 26.5% in the fourth quarter, selling 12,946 shares and retaining 35,874 shares valued at $4.88 million. Agilent Technologies reported Q1 EPS of $1.36 and revenue of $1.80 billion, slightly missing analyst estimates, and announced a quarterly dividend of $0.255. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $161.20 among analysts.
[8-K/A] AGILENT TECHNOLOGIES, INC. Amends Material Event Report
Agilent Technologies, Inc. filed an amended Form 8-K/A to correct an EDGAR header error, reclassifying a previous filing under Item 5.02 regarding changes in officers and compensatory arrangements. The amendment clarifies the disclosure of a transition and general release agreement with Senior Vice President, Chief Legal Officer, and Secretary Bret DiMarco, who will resign from his roles but continue as a Special Advisor. His compensation arrangements as a Special Advisor and post-service lump sum payment are detailed, with the rest of the original disclosure remaining unchanged.
Keysight Technologies Inc. $KEYS Shares Sold by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC significantly cut its stake in Keysight Technologies Inc. (NYSE:KEYS) by 44.1% during the fourth quarter, selling 23,461 shares. Despite insider selling by corporate officers, institutional investors, including Vanguard Group, State Street Corp, and Boston Partners, collectively own a substantial 84.58% of the company's stock. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $304.17, following a strong Q4 earnings beat and positive FY2026 guidance.
Is It Time To Revisit Agilent Technologies (A) After Recent Share Price Weakness
Agilent Technologies (A) stock has seen recent weakness, with a 1.4% return over 7 days and a 17.0% decline year-to-date. A Discounted Cash Flow (DCF) analysis suggests the stock is fairly valued at around $125.14, implying an 8.5% intrinsic discount from its current price of $114.54. However, the company's P/E ratio of 25.1x is below the industry average but considered overvalued compared to Simply Wall St's Fair Ratio of 22.4x.
Lab chromatographs are getting smarter: what Agilent is quietly changing for US labs
This article discusses how Agilent Technologies Inc. and other manufacturers are transforming US labs with smarter, more automated chromatographs. These new systems enhance throughput, compliance, and uptime through automation, AI-assisted analytics, and improved data integrity, moving beyond raw performance to focus on system-level intelligence and workflow efficiency. The piece highlights the benefits for labs struggling with staffing and regulatory burdens, positioning upgrades as a workflow redesign rather than just an instrument purchase.
Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Officer Henson Meghan
This document is a Statement of changes in beneficial ownership of securities for Agilent Technologies, specifically for officer Henson Meghan. This type of filing is typically made with the SEC to report transactions in company stock by insiders.
Agilent (NYSE: A) SVP surrenders shares to cover RSU tax bill
Agilent's Senior Vice President, Meghan Henson, surrendered 153 shares of common stock at a value of $113.98 per share to cover tax withholding on the vesting of restricted stock units. This was an administrative tax disposition, not an open-market trade, and she now directly holds 6,890 shares. The transaction, reported in a Form 4 SEC filing, was conducted in accordance with Rule 16b-3, which exempts certain insider transactions from short-swing profit rules.
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies has launched the BioTek Cytation 9 cell imaging multimode reader, enhancing its Cytation portfolio. This new instrument combines multimode microplate reading and high-content cell imaging, offering expanded capabilities and faster throughput for diverse research applications. Designed with customer feedback, it aims to accelerate discoveries in cell biology and drug development by streamlining workflows for both cell-based and biochemical assays.
Agilent Technologies “in country, for country” strategy helps mitigate supply disruptions
Agilent Technologies has implemented an "in country, for country" manufacturing strategy and diversified supply chains to build resilience against global disruptions. This approach has prevented material impact to their supply chain, even amidst current geopolitical tensions. The company recently opened a Customer Experience Center in Mumbai and a refurbishment center in Manesar, emphasizing their commitment to local services and affordable solutions for customers in India.
Agilent expands India’s scientific ecosystem with new customer experience centre in Mumbai
Agilent Technologies Inc. has opened a new Customer Experience Center (CEC) and office in Mumbai to strengthen its commitment to India's life sciences, pharmaceutical, and applied markets. This facility integrates technology demonstrations, application expertise, and commercial operations to support laboratories across the analytical and application lifecycle. This investment reinforces Agilent's ongoing expansion in India, complementing its existing centers and fostering collaboration with local teams and customers.
Agilent expands India’s scientific ecosystem with new customer experience centre in Mumbai
Agilent Technologies has opened a new Customer Experience Centre (CEC) and office in Mumbai, strengthening its commitment to India's life sciences, pharmaceutical, and applied markets. This facility provides hands-on technology demonstrations, application expertise, and commercial operations, complementing Agilent's existing footprint in India. The investment aims to enhance customer engagement, support laboratory modernization, and foster collaboration within India's rapidly evolving scientific ecosystem.
Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents
Synthego announced that the U.S. Supreme Court has denied Agilent Technologies' petition, thereby finalizing the invalidation of two Agilent CRISPR-related patents. This decision concludes a multi-year legal challenge regarding widely used guide RNA (gRNA) modifications and removes a significant barrier to innovation in CRISPR-enabled research and therapeutics. Synthego's CEO, Craig Christianson, emphasized the company's commitment to fostering an open intellectual property landscape for the scientific community, especially as Synthego expands its leadership in cell and gene therapy with novel nucleases.
Worldwide Factors Influencing the Rapid Evolution of the Life Science Tools Market
The life science tools market is projected to reach $379.95 billion by 2030, growing at a CAGR of 13.5%. This growth is fueled by automation, increased investments in genomics and proteomics, demand for personalized medicine, and advancements in clinical diagnostics and drug discovery. Key players like F. Hoffmann-La Roche Ltd. and Thermo Fisher Scientific Inc. are driving innovation, exemplified by strategic acquisitions and the development of advanced sequencing platforms such as Illumina's MiSeq i100 series.
Key Factors and Emerging Trends Shaping the Lab Supplies Market Landscape
The lab supplies market is set to reach $60.9 billion by 2030, growing at an 8.5% CAGR, driven by advancements in life sciences, diagnostics, and automation. Key trends include increased demand for premium consumables, automated equipment, and a focus on safety and sustainability. Leading companies like Thermo Fisher Scientific and Danaher Corporation are innovating to enhance accuracy and efficiency, with acquisitions like Calibre Scientific's purchase of Dynalab Corp. expanding market reach and product portfolios.
Agilent Technologies Inc Announces the Biotek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies, Inc. has launched the BioTek Cytation 9 cell imaging multimode reader, the latest addition to its Cytation portfolio. This new instrument combines multimode microplate reading and high-content cell imaging, streamlining workflows for researchers from basic investigation to high-throughput screening in pharmaceutical and biotechnology labs. The Cytation 9 offers expanded imaging capabilities and advanced hybrid microplate detection for diverse cellular and biochemical assays.
Flow Cytometry Market Is Booming So Rapidly | Agilent Technologies Inc. • Danaher • Enzo Life Sciences Inc
The Flow Cytometry market is projected to grow significantly, from USD 8.35 billion in 2025 to USD 17.34 billion by 2032, at a CAGR of 11.0%. A new research report offers detailed economic predictions, competitive landscape analysis, and supply chain insights, covering key players such as Agilent Technologies Inc., Danaher, and Enzo Life Sciences Inc. The report also highlights regional outlooks and employs a robust research methodology to provide comprehensive market insights.
Agilent Technologies, Inc. $A Shares Purchased by Vaughan Nelson Investment Management L.P.
Vaughan Nelson Investment Management L.P. significantly increased its stake in Agilent Technologies (NYSE:A) by 11.4% in the fourth quarter, reflecting increasing institutional interest alongside other major firms like AQR and Ameriprise. Agilent reported Q4 EPS of $1.36 and revenue of $1.80 billion, slightly missing estimates, but provided an optimistic FY2026 EPS guidance of $5.900-$6.040, which is above consensus. The company also declared a quarterly dividend of $0.255, with shares trading at a market capitalization of $32.19 billion and a P/E ratio of 25.14.
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook
Qiagen N.V. (ISIN: NL0012169213), a prominent molecular diagnostics leader, is undergoing a CEO transition while maintaining its 5% growth target for the year. North American investors are advised to monitor leadership changes, new product launches, and the company's strategic focus on innovation and sustainability. The company's resilience, diversified portfolio, and strong position in genomics tools make it an appealing option despite sector headwinds.
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies, Inc. announced the launch of the BioTek Cytation 9 cell imaging multimode reader, which integrates multimode microplate reading and high-content cell imaging into a single platform. This new instrument builds on a decade of Cytation innovation, offering expanded imaging capabilities and advanced hybrid microplate detection for faster workflows in basic research and high-content screening. Designed for both cell-based and biochemical assays, the Cytation 9 aims to accelerate discoveries in cell biology and drug development, particularly for pharmaceutical and biotechnology laboratories.
Key Factors and Emerging Trends Shaping the Life Science and Chemical Instrumentation Market Landscape
The life science and chemical instrumentation market is projected to reach $90.58 billion by 2030, driven by advanced omics technologies, personalized medicine research, and digital laboratories. Key trends include automated analytical instruments, high-throughput testing, and enhanced integration of laboratory information management systems, with major players like Agilent Technologies and Thermo Fisher Scientific leading innovation. Recent acquisitions, such as Spectris acquiring Micromeritics, highlight strategic moves to expand portfolios and leverage specialized expertise in this rapidly evolving sector.
Agilent Technologies, Inc. $A Shares Sold by Scharf Investments LLC
Scharf Investments LLC reduced its stake in Agilent Technologies (NYSE:A) by 6.4% in the fourth quarter, selling over 36,000 shares but still holding a significant position valued at $72.29 million. The medical research company recently reported Q4 results with EPS slightly below estimates and revenue up 7% year-over-year, while also declaring a quarterly dividend of $0.255 per share. Analysts generally maintain a "Moderate Buy" rating for Agilent Technologies, with a consensus price target of $161.20.
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies has launched the BioTek Cytation 9 cell imaging multimode reader, the latest addition to its Cytation portfolio. This new instrument combines multimode microplate reading and high-content cell imaging in a single platform, designed to accelerate research from basic studies to high-content screening. Building on previous innovations and customer feedback, the Cytation 9 offers expanded imaging capabilities and advanced microplate detection technologies, aiming to support more rigorous research demands in pharmaceutical and biotechnology laboratories.
Thermo Fisher’s Glacios 3 Cryo TEM Puts AI At Center Of Growth
Thermo Fisher Scientific recently unveiled its Glacios 3 Cryo-TEM, an advanced cryo electron microscope incorporating AI-supported tools and improved imaging clarity. This new system is designed to accelerate drug discovery and structural studies by reducing practical barriers to adoption. For investors, the launch represents a significant product milestone for the company, highlighting its focus on high-impact analytical tools and AI in drug development.
Does Thermo Fisher’s New SHL Autoinjector Hub Reshape Its Device Integration Strategy For TMO?
Thermo Fisher Scientific has partnered with SHL Medical to establish an integrated U.S. hub for sterile fill-finish, autoinjector assembly, and commercial packaging, strengthening its role as an end-to-end partner for pharmaceutical and biotech companies. This collaboration, featuring SHL Medical's Molly autoinjector platform, aims to enhance Thermo Fisher's biopharma services, complementing its global sterile manufacturing network. While this move supports Thermo Fisher's long-term growth and high-value services, investors should also consider external risks like tariffs, policy shifts, and a growing dependence on acquisitions.
Thermo Fisher Scientific Stock: Leading Life Sciences Provider Faces Mixed Institutional Flows Amid Strong Fundamentals
Thermo Fisher Scientific, a global leader in life sciences, reported strong quarterly results in January 2026, beating earnings expectations with significant revenue growth. Despite high institutional ownership and bullish analyst ratings, some investors have trimmed stakes, signaling caution. The company shows strong financials, dividend growth potential, and strategic developments, making it a key play for North American investors in healthcare innovation.
Agilent Technologies Inc. stock rises Tuesday, still underperforms market
Agilent Technologies Inc. (A) stock increased by 1.99% on Tuesday, closing at $113.98. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index rose 2.91% and the Dow Jones Industrial Average rose 2.49%. This marks the second consecutive day of gains for Agilent Technologies Inc.
SNP Genotyping and Analysis Market to See Booming Growth
The SNP Genotyping and Analysis Market is anticipated to experience significant growth from 2026 to 2033, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscapes. The report aims to provide stakeholders with actionable insights for informed, data-driven decisions amidst global market dynamics.
J. Safra Sarasin Holding AG Sells 39,952 Shares of Agilent Technologies, Inc. $A
J. Safra Sarasin Holding AG reduced its stake in Agilent Technologies (NYSE:A) by 18.1% in the fourth quarter, selling 39,952 shares and holding 180,319 shares valued at $24.54 million. Despite this, other institutional investors increased their positions, and analysts maintain a "Moderate Buy" rating with a consensus target price of $161.20 for Agilent. The company recently announced a quarterly dividend and reported earnings slightly below consensus.
Dissolution Online Systems Market Is Going to Boom | Agilent Technologies • Merck KGaA • PerkinElmer
A new report by Coherent Market Insights analyzes the Dissolution Online Systems Market from 2026 to 2033, highlighting key trends, drivers, and challenges. The report provides a deep dive into market size, revenue, and production, focusing on the competitive landscape and growth opportunities. It features insights into major companies like Agilent Technologies and Merck KGaA, alongside a comprehensive segmentation by product types, applications, and regions.
Is Danaher’s BIO-Europe Spring Focus Sharpening Its Life Sciences Edge or Simply Polishing the Story (DHR)?
Danaher Corporation recently presented at BIO-Europe Spring 2026, highlighting its life sciences tools and diagnostics capabilities. While this presentation offers visibility, the company's near-term demand is still tied to early-stage biotech recovery and policy pressures in China. Danaher's investment narrative projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a substantial upside.
Agilent Technologies Inc. stock outperforms competitors on strong trading day
Agilent Technologies Inc. (A) stock rose 1.61% to $112.01 on Monday, outperforming the S&P 500 Index despite a mixed trading session. The company's stock closed 30.11% below its 52-week high of $160.27, achieved on November 25th.
Agilent Technologies price faces negative outlook - Forecast today - 30-03-2026
The Agilent Technologies (A) stock price is facing a negative outlook due to a short-term corrective downtrend, trading below its 50-day simple moving average, and a negative divergence forming on the Relative Strength Index. Analysts expect the stock to decline in upcoming trading sessions, targeting a support level of $107.00 as long as the resistance level at $116.40 holds. This forecast is bearish for the stock.
International Paper price shows more signs of weakness - Forecast today - 30-03-2026
International Paper (IP) stock is forecast to decline in upcoming trading sessions due to a dominant downward trend and negative pressure from trading below its 50-day simple moving average. The Relative Strength Index shows early signs of a bearish crossover after reaching overbought levels. Analysts expect the stock to target a key support level at $33.60, provided the resistance at $38.00 holds.
Agilent Technologies Adjusts Valuation Amid Strong Institutional Support and Financial Metrics
Agilent Technologies has seen its valuation grade shift from "very attractive" to "attractive," reflecting a refined assessment of its financial health and market standing. Key financial metrics include a P/E ratio of 22, an 18.80% return on capital employed, and a low debt-to-EBITDA ratio of 0.90 times. Despite flat operating cash flow, the company maintains strong institutional support with 93.78% holdings.
Agilent Technologies' Advanced Chromatography Solutions: Driving Precision Analytics in North Americ
Agilent Technologies' chromatography solutions are essential for precision analytics in North American labs, especially with the rise of AI-driven research. Their GC and LC systems offer high accuracy for pharmaceutical, biotech, and environmental testing, positioning Agilent as a key player in the growing lab technology market. The company's innovations, market applications across diverse sectors, and strategic integration with AI platforms underscore its strong competitive position and growth prospects for investors.
Agilent Technologies' Advanced Chromatography Solutions: Driving Precision Analytics in North Americ
Agilent Technologies is positioned as a key player in analytical science, particularly in chromatography, with its GC and LC systems being essential for pharmaceutical, biotech, and environmental testing. The article highlights how Agilent's precision instruments are crucial for AI-driven research, enabling high-quality data for machine learning models and accelerating drug discovery and materials analysis. For investors, Agilent offers a stable investment in the growing lab tech market, bolstered by its technological superiority, diverse market applications, and strong financial performance.
Food Testing Kits Market Is Going to Boom | Thermo Fisher Scientific • Eurofins Scientific • SGS SA
A new report by Coherent Market Insights analyzes the Food Testing Kits Market, projecting substantial growth from 2026 to 2033. The report covers market trends, drivers, challenges, and the competitive landscape, highlighting key players, technological innovations, and investment potential. It provides a comprehensive segmentation including product types, applications, end-user markets, and geographical regions, aimed at empowering businesses with actionable insights for strategic decision-making.
